99 related articles for article (PubMed ID: 12565723)
21. Effects of the new potassium channel opener JTV-506 on coronary vessels in vitro and in vivo.
Hirata Y; Kanada A; Miyai H; Mabuchi Y; Aisaka K
Arzneimittelforschung; 1999 Mar; 49(3):199-206. PubMed ID: 10219462
[TBL] [Abstract][Full Text] [Related]
22. Beneficial effect of low molecular weight heparin on the hemodialysis model in dogs.
Hamano S; Komatsu H; Ikeda S; Takahashi K; Oguma Y; Sakuragawa N
Thromb Res; 1989 Aug; 55(4):439-49. PubMed ID: 2554525
[TBL] [Abstract][Full Text] [Related]
23. [Biological activity of enoxaprine (PK 10169) in hemodialysis. A dose study].
Pouzol P; Polack B; Dechelette E; Jurkovitz C; Cusin E
J Mal Vasc; 1987; 12 Suppl B():108-10. PubMed ID: 2834480
[TBL] [Abstract][Full Text] [Related]
24. Antithrombotic effect of YM-75466 is separated from its effect on bleeding time and coagulation time.
Sato K; Kaku S; Hirayama F; Koshio H; Matsumoto Y; Kawasaki T; Iizumi Y
Eur J Pharmacol; 1998 Jul; 352(1):59-63. PubMed ID: 9718268
[TBL] [Abstract][Full Text] [Related]
25. Haemodialysis with low MW heparin: dosage requirements for the elimination of extracorporeal fibrin formation.
Lane DA; Ireland H; Flynn A; Anastassiades E; Curtis JR
Nephrol Dial Transplant; 1986; 1(3):179-87. PubMed ID: 2955253
[TBL] [Abstract][Full Text] [Related]
26. A primate model (Macaca mulatta) to study the pharmacokinetics of heparin and its fractions.
Fareed J; Kumar A; Rock A; Walenga JM; Davis P
Semin Thromb Hemost; 1985 Apr; 11(2):138-54. PubMed ID: 4035364
[TBL] [Abstract][Full Text] [Related]
27. Citrate compared to low molecular weight heparin anticoagulation in chronic hemodialysis patients.
Janssen MJ; Deegens JK; Kapinga TH; Beukhof JR; Huijgens PC; van Loenen AC; van der Meulen J
Kidney Int; 1996 Mar; 49(3):806-13. PubMed ID: 8648924
[TBL] [Abstract][Full Text] [Related]
28. Kinetics of anti-Xa activity during combined defibrotide-heparin administration in hemodialysis.
Buccianti G; Valenti G; Lorenz M; Cresseri D; Strada E; Nazzari M
Int J Artif Organs; 1990 Jul; 13(7):416-20. PubMed ID: 2401580
[TBL] [Abstract][Full Text] [Related]
29. Antithrombotic activity of a synthetic heparin pentasaccharide in a rabbit stasis thrombosis model using different thrombogenic challenges.
Walenga JM; Petitou M; Lormeau JC; Samama M; Fareed J; Choay J
Thromb Res; 1987 Apr; 46(2):187-98. PubMed ID: 3603420
[TBL] [Abstract][Full Text] [Related]
30. Anticoagulant effects of a low molecular weight heparinoid (Org 10172) in human volunteers and haemodialysis patients.
ten Cate H; Henny CP; ten Cate JW; Büller HR; Mooy MC; Surachno S; Wilmink JM
Thromb Res; 1985 Jul; 39(2):211-22. PubMed ID: 3161213
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of coagulation and anti-Xa factor when using a heparin-coated AN69ST® dialyser.
Sánchez-Canel JJ; Pons-Prades R; Salvetti ML; Seores A; Vázquez M; Pérez-Alba A; Tamarit E; Calvo-Gordo C; Villatoro J
Nefrologia; 2012; 32(5):605-12. PubMed ID: 23013946
[TBL] [Abstract][Full Text] [Related]
32. Anticoagulant efficacy of PEG-Hirudin in patients on maintenance hemodialysis.
Pöschel KA; Bucha E; Esslinger HU; Ulbricht K; Nörtersheuser P; Stein G; Nowak G
Kidney Int; 2004 Feb; 65(2):666-74. PubMed ID: 14717940
[TBL] [Abstract][Full Text] [Related]
33. Minimal intermittent heparinization during hemodialysis.
Willimann P; Alig A; Binswanger U
Nephron; 1979; 23(4):191-93. PubMed ID: 471142
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of pentasaccharide in a dog model of hemodialysis.
Hoppensteadt DA; Jeske WP; Walenga JM; Fu K; Yang LH; Ing T; Herbert JM; Fareed J
Thromb Res; 1997 Oct; 88(2):159-70. PubMed ID: 9361369
[TBL] [Abstract][Full Text] [Related]
35. Radionuclide method for evaluating the performance of hemodialysis in vivo.
Bihl GR; Bird NJ; Peters C; Bradley JR; Peters AM
Kidney Int; 2005 Feb; 67(2):721-31. PubMed ID: 15673322
[TBL] [Abstract][Full Text] [Related]
36. Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents.
Fukuda T; Honda Y; Kamisato C; Morishima Y; Shibano T
Thromb Haemost; 2012 Feb; 107(2):253-9. PubMed ID: 22186946
[TBL] [Abstract][Full Text] [Related]
37. Inhibitory effects of JTV-519, a novel cardioprotective drug, on potassium currents and experimental atrial fibrillation in guinea-pig hearts.
Nakaya H; Furusawa Y; Ogura T; Tamagawa M; Uemura H
Br J Pharmacol; 2000 Dec; 131(7):1363-72. PubMed ID: 11090108
[TBL] [Abstract][Full Text] [Related]
38. Rationale for the use of a low molecular weight heparin during hemodialysis with polysulphone membrane in uremic patients.
Moia M; Graziani G; Tenconi PM; Martinelli I; Ponticelli C
Ann Ital Med Int; 1997; 12(2):67-71. PubMed ID: 9284597
[TBL] [Abstract][Full Text] [Related]
39. Direct and rapid inhibition of factor Xa by otamixaban: a pharmacokinetic and pharmacodynamic investigation in patients with coronary artery disease.
Hinder M; Frick A; Jordaan P; Hesse G; Gebauer A; Maas J; Paccaly A
Clin Pharmacol Ther; 2006 Dec; 80(6):691-702. PubMed ID: 17178269
[TBL] [Abstract][Full Text] [Related]
40. The anticoagulant and hemorrhagic effects of DHG, a new depolymerized holothurian glycosaminoglycan, on experimental hemodialysis in dogs.
Minamiguchi K; Kitazato KT; Sasaki E; Nagase H; Kitazato K
Thromb Haemost; 1997 Jun; 77(6):1148-53. PubMed ID: 9241748
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
